

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Muimo et al.)
)
Serial No.: To be assigned)
(Continuation of)
PCT/GB00/00736))
)
Filed: Herewith)
)
For: METHODS OF DETERMINING)
ALTERED NDPK FUNCTIONS)
AND THE DIAGNOSIS OF)
CYSTIC FIBROSIS)
_____)

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231
Box: Patent Application

Sir:

Please amend the above-identified patent application
as follows:

In the Specification:

Please insert the following new paragraph on page 1,
line 2 prior to the first paragraph:

"This application is a continuation of PCT/GB00/00736,
filed March 2, 2000, which claims priority to U.S. Provisional
Patent Application Serial No. 60/122,426, filed March 2, 1999,
which are hereby incorporated by reference."

In the Claims:

Please amend claims 6, 12, 13, 20, 23, 32, 33, 36,
39 , 40, 45 and 48, cancel claims 24, 27, 38 and 42 and insert
new claims 51-57 as follows:

6. (Amended) A method according to claim 1 wherein the epithelial cell sample from the patient is a lung cell sample or a nasal cell sample.

12. (Amended) A method according to claim 7 wherein the epithelial cell sample from the patient is a lung cell sample or a nasal cell sample.

13. (Amended) A method according to claim 7 wherein the effectiveness of a treatment for cystic fibrosis is being tested on the patient.

20. (Amended) A method according to claim 14 wherein the method is carried out *in vivo*.

23. (Amended) A compound identified by the method of claim 14.

32. (Amended) A peptide according to claim 31 which comprises SEQ. ID. NO. 1.

33. (Amended) A peptide according to claim 28 further comprising a lipid-solubilising moiety.

36. (Amended) A peptide according to claim 33 wherein the lipid-solubilising moiety is a fatty acid.

39. (Amended) A pharmaceutical formulation comprising a peptide according to claim 28 and a pharmaceutically acceptable carrier.

40. (Amended) A method of treating cystic fibrosis or a chronic sputum producing disorder, the method comprising administering to a patient an effective amount of a peptide according to claim 28.

45. (Amended) A peptide according to claim 43 wherein the histidine residue is phosphorylated.

48. (Amended) An antibody obtainable by the method of claim 46.

Pursuant to 37 CFR §1.121(c)(1)(iii), a marked up version of these claims accompanies this amendment.

51. (New) A method according to claim 4 wherein the epithelial cell sample from the patient is a lung cell sample or a nasal cell sample.

52. (New) A method according to claim 17 wherein the method is carried out *in vivo*.

53. (New) A method according to claim 19 wherein the method is carried out *in vivo*.

53. (New) A compound identified by the method of claim 17.

54. (New) A compound identified by the method of claim 19.

55. (New) A compound identified by the method of claim 21.

56. (New) A peptide according to claim 44 wherein the histidine residue is phosphorylated.

57. (New) An antibody obtainable by the method of claim 47.

REMARKS

In view of the foregoing, applicants submit that this case is in condition for allowance and such allowance is earnestly solicited.

Respectfully submitted,

August 31, 2001
Date

Karla M. Weyand
Karla M. Weyand
Registration No. 40,223

Braman & Rogalskyj, LLP
P.O. Box 352
Canandaigua, New York 14424-0352
Tel: 716-626-5380
Fax: 716-626-5384

FOIEBO" 0E044660

APPENDIX

6. (Amended) A method according to [any one of Claims] claim 1 [to 5] wherein the epithelial cell sample from the patient is a lung cell sample or a nasal cell sample.

12. (Amended) A method according to [any one of Claims] claim 7 [to 11] wherein the epithelial cell sample from the patient is a lung cell sample or a nasal cell sample.

13. (Amended) A method according to [any one of Claims] claim 7 [to 11] wherein the effectiveness of a treatment for cystic fibrosis is being tested on the patient.

20. (Amended) A method according to [any one of Claims] claim 14 [to 19] wherein the method is carried out *in vivo*.

23. (Amended) A compound identified by the method of [any one of Claims] claim 14 [to 22].

32. (Amended) A peptide according to [any one of Claims 28 to] claim 31 which [has the sequence KENIIFGVSYDEYR] comprises SEQ. ID. NO. 1.

33. (Amended) A peptide according to [any one of Claims] claim 28 [to 32] further comprising a lipid-solubilising moiety.

36. (Amended) A peptide according to [Claims] claim 33 [or 34] wherein the lipid-solubilising moiety is a fatty acid.

39. (Amended) A pharmaceutical formulation

